Thrombus and
cardiovascular diseases pose a significant health threat, and dietary interventions have shown promising potential in reducing the incidence of these diseases. Marine bioactive
proteins and
peptides have been extensively studied for their antithrombotic properties. They can inhibit platelet activation and aggregation by binding to key receptors on the platelet surface. Additionally, they can competitively anchor to critical
enzyme sites, leading to the inhibition of
coagulation factors. Marine microorganisms also offer alternative sources for the development of novel fibrinolytic
proteins, which can help dissolve
blood clots. The advancements in technologies, such as targeted hydrolysis, specific purification, and encapsulation, have provided a solid foundation for the industrialization of bioactive
peptides. These techniques enable precise control over the production and delivery of bioactive
peptides, enhancing their efficacy and safety. However, it is important to note that further research and clinical studies are needed to fully understand the mechanisms of action and therapeutic potential of marine bioactive
proteins and
peptides in mitigating thrombotic events. The challenges and future application perspectives of these bioactive
peptides also need to be explored.